Earnings Releases·Nov 5, 2026, 7:12 AM ET

Xeris Biopharma — Third Quarter 2026 Earnings Summary

Total revenue rose 44% year-over-year to $107.2 million in Q3 2026, driven by a 93% surge in Recorlev net revenue to $71.5 million, while gross margin improved to 88% and adjusted EBITDA increased $13.3 million year-over-year to $30.8 million.
Full-year 2026 revenue guidance was raised to $395–$405 million, and the 2030 revenue outlook was upgraded to exceed $1 billion, with Recorlev projected to reach nearly $1 billion in annual net revenue three to four years sooner than previously anticipated.
The company fully retired all 8.00% Convertible Senior Notes due 2028, eliminating approximately $34 million in debt and $3 million in annual interest expense, while advancing the pivotal Phase 3 Cornerstone study for XP-8121 with topline data expected in late 2028.
Nine-month net loss was $17.6 million, though this included a $30.8 million one-time non-cash charge related to the convertible notes exchange; adjusted EBITDA for the period improved $30.8 million year-over-year to $65.1 million.